Video
Fred Eckel, RPh, MS, Editor-in-Chief of Pharmacy Times, reflects on how pharmacists will be affected by FDA approvals of biosimilars.
Fred Eckel, RPh, MS, Editor-in-Chief of Pharmacy Times, reflects on how pharmacists will be affected by FDA approvals of biosimilars.
This video was recorded at APhA’s Annual Meeting and Exposition in March 2015.
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria